Alpha Tau Medical Ltd. (DRTS)
Develops radioactive cancer treatments that target solid tumors
$11.55-0.05%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+287.6%
The outlook
DRTS is trading near its recent highs, sitting 77% of the way up its 52-week range. Analysts lean strongly bullish with a buy consensus, and the average price target sits roughly 23% above the current level. The stock is holding above both its 50- and 200-day moving averages, reflecting a sustained uptrend.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range77% of the way from its 52-week low to high
Price targetAvg target +23% vs current price
Analyst price target
~12-month · 5 analysts$14.20average target+22.9% vs now
Now $11.55
Low $8.00High $17.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.04B
52-wk high
$14.11
52-wk low
$2.87
50-day avg
$11.15
200-day avg
$7.40
Trailing P/E
—